BENEFIT-HFNCT07232030
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 30 versions: 28 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 23 → 26 locations
- Minor Study sites: 23 to 24
- Minor Trial sites expanded: 20 → 23 locations
- Minor Study sites: 21 to 22
- Minor Study sites: 20 to 21
- Minor Trial sites expanded: 14 → 20 locations
- Minor Study sites: 13 to 14
- Minor Study sites: 12 to 13
- Notable Eligibility criteria expanded, about 44 words
- Study sites: 11 to 12
- Minor Study sites: 10 to 11v21
- Minor Study sites: 9 to 10v20
- Minor Trial status changed: Enrolling by Invitation → Recruiting
- Site contacts updated at 3 of 9 sites
- Minor Trial status: Enrolling by Invitation to Recruiting
- Study sites: 8 to 9
- Minor Study sites: 7 to 8v17
- Minor Study sites: 6 to 7v16
- Minor Study sites: 5 to 6v14
- Minor Study sites: 4 to 5v13
- Minor Study sites: 3 to 4
- Start date changed from estimate of Apr 2026 to Apr 24, 2026
- Minor Study sites: 2 to 3v10
- Minor Trial status changed: Recruiting → Enrolling by Invitation
- Site details revised at 2 of 2 sites
- Minor Site details revised at 1 of 2 sitesv8
- Minor Site contacts updated at 1 of 2 sitesv7
- Minor Study sites: 1 to 2v6
- Minor Site contact updatedv5
- Notable Recruitment opened
- Start date: Mar 2026 to Apr 2026
- Site details revised
- Minor Study sites: 0 to 1v3
- Notable Eligibility criteria shortened, about 2 words
- Secondary endpoints: details revised at 2 of 5 entries
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Primary Effectiveness Endpoint
Timeframe: Through 24-months follow-up
Primary Safety Endpoint
Timeframe: Within 180 days of the device implant
Secondary (5)
Quality of Life (QoL) Score Change
6MHW distance change
Days lost to death or hospitalization
NT-proBNP level change
All-cause mortality
Arms and interventions
Device ArmExperimental
Participants will receive Baroreflex Activation Therapy (BAT) with an implanted Barostim System in addition to usual care medical management.
Control ArmActive comparator
Participants will receive usual care medical management alone with no Barostim System device implant.
Devices: Barostim System
Other: Usual care medical management
Sites
26 sites in 1 country